The state of Florida currently has 39 active clinical trials seeking participants for Parkinson's Disease research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Use of CereGate Therapy for Freezing of Gait in PD
NCT05292794
Recruiting
A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
05/28/2025
Locations: University of Miami, Miami, Florida
Conditions: Parkinson Disease, Freezing of Gait, Deep Brain Stimulation
Register for Updates
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
NCT06944522
Recruiting
Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
05/28/2025
Locations: Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida
Conditions: Parkinsons Disease (PD)
Register for Updates
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
NCT06765668
Recruiting
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Visionary Investigators Network, Aventura, Florida +2 locations
Conditions: Parkinson Disease
Register for Updates
Parkinson's Foundation PD GENEration Genetic Registry
NCT04994015
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Aventura Neurology - Visionary Investigators Network, Aventura, Florida +4 locations
Conditions: Parkinson's Disease
Register for Updates
Lu AF28996 in Participants With Parkinson's Disease (PD)
NCT04291859
Recruiting
The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
Gender:
ALL
Ages:
Between 35 years and 85 years
Trial Updated:
05/07/2025
Locations: Velocity, Hallandale Beach, Florida +1 locations
Conditions: Parkinson Disease
Register for Updates
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
NCT04127578
Recruiting
Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogeni... Read More
Gender:
ALL
Ages:
Between 35 years and 80 years
Trial Updated:
05/05/2025
Locations: K2 Medical Research, 101 Southhall Lane, Suite 150, Maitland, Florida +1 locations
Conditions: Parkinson Disease
Register for Updates
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
NCT05395624
Recruiting
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/30/2025
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Register for Updates
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
NCT04991831
Recruiting
The objectives of this study are to collect the long-term safety and effectiveness data of performing thalamotomy for tremor dominant Parkinson's Disease (TDPD) using the Exablate Neuro system.
Gender:
ALL
Ages:
Between 30 years and 99 years
Trial Updated:
04/29/2025
Locations: Miami Neuroscience Institute Baptist Health, Miami, Florida
Conditions: Tremor Associated With Tremor Dominant Parkinson's Disease
Register for Updates
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
NCT05266417
Recruiting
This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
04/29/2025
Locations: Institute for Neuroimmune Medicine, Davie, Florida +1 locations
Conditions: Parkinson Disease
Register for Updates
Studies of the Variable Phenotypic Presentations of Rapid-Onset Dystonia Parkinsonism and Other Movement Disorders
NCT00682513
Recruiting
The purposes of this study are to identify persons with rapid-onset dystonia-parkinsonism (RDP) or mutations of the RDP gene, document prevalence of the disease, and map its natural history.
Gender:
ALL
Ages:
All
Trial Updated:
04/28/2025
Locations: University of Miami, Miami, Florida
Conditions: Dystonia, Parkinsonism
Register for Updates
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
NCT06822517
Recruiting
This trial is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients with mild to moderate Parkinson's disease. The study includes a screening period, a 28-day double-blind treatment period, and a 7-day follow-up period after last dose. Approximately 30 patients will be randomized into 1 of the 2 treatment arms.
Gender:
ALL
Ages:
Between 45 years and 90 years
Trial Updated:
04/21/2025
Locations: Investigative Site, Aventura, Florida +11 locations
Conditions: Parkinson Disease
Register for Updates
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
NCT04477785
Recruiting
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
03/28/2025
Locations: Parkinson's Disease& Movement Disorder Center of Boca Raton, Boca Raton, Florida +2 locations
Conditions: Parkinson Disease
Register for Updates